XERS · Xeris Biopharma Holdings Inc
United States · RS rating 90 · As of 2026-11-03
| Price | 10.35 USD |
|---|---|
| 1-day change | +1.8% |
| RS rating (overall / 1M / 3M / 12M) | 90 / 64 / 92 / 57 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 55 / 76 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -83.3% |
| Sales growth Q/Q | +15.4% |
| Distance from 52-week high | +7.0% |
| Market cap (USD) | $1.0B |